UroGen Pharma

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEHR

ATCH

ATPC

AVGR

CANG

CHCI

HCWC

LIDR

NMHI

PHIO

PIII

RGNX

RIME

SANG

STAF

URGN

YOSH

Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

PriceSmart

ORIC

PSMT

ROKU

VINP

PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

BTDR

NTES

RXRX

NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

UroGen Pharma Ltd

Press Releases

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

UroGen Pharma to Present at Upcoming Investor Conferences

Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

UroGen Pharma Ltd. (NASDAQ: URGN), CS Diagnostics Corp. (OTCQB: CSDX) and Boston Scientific (NYSE: BSX) Advancing Cancer Treatment Technology – More Stocks Inside

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102

Comments

UroGen Pharma

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga